Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 10 studies | 29% ± 10% | |
hepatocyte | 4 studies | 55% ± 17% | |
oligodendrocyte | 3 studies | 20% ± 3% |
Insufficient scRNA-seq data for expression of HSD11B1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 13485.97 | 226 / 226 | 92% | 512.31 | 374 / 406 |
lung | 100% | 2136.16 | 576 / 578 | 86% | 13.68 | 993 / 1155 |
prostate | 98% | 1638.05 | 240 / 245 | 79% | 8.17 | 395 / 502 |
ovary | 99% | 3067.09 | 179 / 180 | 51% | 4.17 | 218 / 430 |
bladder | 86% | 655.62 | 18 / 21 | 56% | 5.94 | 283 / 504 |
skin | 99% | 1678.23 | 1787 / 1809 | 42% | 5.42 | 197 / 472 |
breast | 82% | 672.98 | 378 / 459 | 58% | 7.37 | 646 / 1118 |
stomach | 57% | 284.72 | 206 / 359 | 62% | 7.42 | 176 / 286 |
brain | 56% | 346.65 | 1484 / 2642 | 55% | 7.50 | 387 / 705 |
lymph node | 0% | 0 | 0 / 0 | 97% | 64.76 | 28 / 29 |
adipose | 96% | 1073.54 | 1156 / 1204 | 0% | 0 | 0 / 0 |
intestine | 41% | 177.09 | 393 / 966 | 54% | 7.15 | 285 / 527 |
esophagus | 54% | 270.30 | 774 / 1445 | 39% | 3.16 | 72 / 183 |
adrenal gland | 77% | 391.17 | 198 / 258 | 16% | 1.53 | 36 / 230 |
pancreas | 6% | 17.29 | 19 / 328 | 86% | 21.21 | 153 / 178 |
thymus | 59% | 273.49 | 385 / 653 | 28% | 1.77 | 168 / 605 |
blood vessel | 86% | 590.86 | 1147 / 1335 | 0% | 0 | 0 / 0 |
spleen | 72% | 318.40 | 173 / 241 | 0% | 0 | 0 / 0 |
uterus | 28% | 93.11 | 47 / 170 | 39% | 4.07 | 179 / 459 |
kidney | 35% | 268.70 | 31 / 89 | 28% | 3.48 | 254 / 901 |
heart | 48% | 200.81 | 409 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 38% | 4.64 | 17 / 45 |
muscle | 31% | 112.30 | 247 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 7.07 | 11 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006706 | Biological process | steroid catabolic process |
GO_0030324 | Biological process | lung development |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0070524 | Molecular function | 11-beta-hydroxysteroid dehydrogenase (NADP+) activity |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0050661 | Molecular function | NADP binding |
GO_0047022 | Molecular function | 7-beta-hydroxysteroid dehydrogenase (NADP+) activity |
GO_0102196 | Molecular function | cortisol dehydrogenase activity |
GO_0005496 | Molecular function | steroid binding |
Gene name | HSD11B1 |
Protein name | Hydroxysteroid 11-beta dehydrogenase 1 11-beta-hydroxysteroid dehydrogenase 1 (11-DH) (11-beta-HSD1) (EC 1.1.1.146) (7-oxosteroid reductase) (EC 1.1.1.201) (Corticosteroid 11-beta-dehydrogenase isozyme 1) (Short chain dehydrogenase/reductase family 26C member 1) 11-beta-hydroxysteroid dehydrogenase 1 (EC 1.1.1.146) (EC 1.1.1.201) (7-oxosteroid reductase) (Corticosteroid 11-beta-dehydrogenase isozyme 1) |
Synonyms | SDR26C1 HSD11L HSD11 |
Description | FUNCTION: Controls the reversible conversion of biologically active glucocorticoids such as cortisone to cortisol, and 11-dehydrocorticosterone to corticosterone in the presence of NADP(H) . Participates in the corticosteroid receptor-mediated anti-inflammatory response, as well as metabolic and homeostatic processes . Plays a role in the secretion of aqueous humor in the eye, maintaining a normotensive, intraocular environment . Bidirectional in vitro, predominantly functions as a reductase in vivo, thereby increasing the concentration of active glucocorticoids . It has broad substrate specificity, besides glucocorticoids, it accepts other steroid and sterol substrates . Interconverts 7-oxo- and 7-hydroxy-neurosteroids such as 7-oxopregnenolone and 7beta-hydroxypregnenolone, 7-oxodehydroepiandrosterone (3beta-hydroxy-5-androstene-7,17-dione) and 7beta-hydroxydehydroepiandrosterone (3beta,7beta-dihydroxyandrost-5-en-17-one), among others . Catalyzes the stereo-specific conversion of the major dietary oxysterol, 7-ketocholesterol (7-oxocholesterol), into the more polar 7-beta-hydroxycholesterol metabolite . 7-oxocholesterol is one of the most important oxysterols, it participates in several events such as induction of apoptosis, accumulation in atherosclerotic lesions, lipid peroxidation, and induction of foam cell formation . Mediates the 7-oxo reduction of 7-oxolithocholate mainly to chenodeoxycholate, and to a lesser extent to ursodeoxycholate, both in its free form and when conjugated to glycine or taurine, providing a link between glucocorticoid activation and bile acid metabolism . Catalyzes the synthesis of 7-beta-25-dihydroxycholesterol from 7-oxo-25-hydroxycholesterol in vitro, which acts as a ligand for the G-protein-coupled receptor (GPCR) Epstein-Barr virus-induced gene 2 (EBI2) and may thereby regulate immune cell migration . . |
Accessions | P28845 A0A0A0MQV1 X5D2L1 A0A087WU76 ENST00000615289.4 ENST00000367028.6 ENST00000367027.5 ENST00000261465.5 |